Nicholas Hornstein: Anticipating Resistance and Revolution Medicines’ Proactive Strategy for RAS Therapy
Nicholas HornsteinAssistant Professor at Northwell Health, shared a put up on LinkedIn:
“Drug growth is meant to be linear.
Build the drug – use the drug – resistance exhibits up – then work out what to do subsequent.
And not what Revolution Medicines is doing.
At AACR26, they revealed RM-055which truthfully, is a singular idea.
Before DaraxONRASib is even absolutely on the earth, they’re constructing round resistance.
How it really works:
- Most mutant RAS proteins are comparatively proof against GAP-mediated hydrolysis
- That helps maintain RAS within the lively state
- They’ve discovered a option to improve that hydrolysis with RM-055
RM-055 can:
- restore hydrolysis in mutant RAS
- flatten daraxonrasib-resistant fashions
- generate exercise even in RAS-amplified settings
That’s a really sensible means to consider this area.
Not simply ‘this is our inhibitor.’
More like: we already know resistance to our medication is coming, so let’s begin constructing now.
“That’s how we cure cancer, no more me-toos (if I hear about another new PD1 program, I’m going to cry).”
Other articles that includes Nicholas Hornstein on OncoDaily.
